Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Radiother Oncol. 2020 May 6;149:142–149. doi: 10.1016/j.radonc.2020.04.053

Table 1.

Patient, tumor, and treatment characteristics

All patients No trismus (≥3 fingers) Mild trismus (≥2 fingers) Moderate/Severe trismus (<2 fingers) p-value
n=587 n=419 (71%) n=154 (26%) n=14 (3%)
Covariate n % n % n % n %
Sex
 Male 492 83.8 348 71 132 27 12 2 0.73
 Female 95 16.2 71 75 22 23 2 2
Mean age (years) ± SD 57.69 8.59 57.52 8.62 58.07 8.53 58.57 8.58 0.67
Initial disease site
 Base of tongue 288 49.1 220 76 64 22 4 2 0.59
 Tonsil 267 45.5 178 67 81 30 8 3
 NOS 17 2.9 10 60 6 35 1 5
 Soft palate 7 1.2 7 100 - - -
 GPS 6 1.0 3 50 2 33 1 17
 Pharyngeal wall 2 0.3 1 50 1 50 - -
HPV/p16 status
 Positive 338 57.6 248 73 84 25 6 2 0.33
 Negative 42 7.1 29 69 13 31 - -
 Unknown 207 35.3 142 68 57 28 8 4
T status
 T1 203 34.6 166 82 34 17 3 1 <0.0001*
 T2 229 39.0 161 70 66 29 2 1
 T3 91 15.5 61 67 27 30 3 3
 T4 61 10.4 29 47 26 42 6 1
 Tx 3 0.5 2 67 1 33
N status
 N0 46 7.8 31 67 14 30 1 2 0.35
 N1 81 13.8 61 75 17 2 3 3
 N2a 62 10.6 47 76 14 22 1 2
 N2b 283 48.2 204 72 76 27 3 1
 N2c 103 17.5 67 65 30 29 6 6
 N3 12 2.0 9 75 3 25 - -
Mean radiation dose ± SD, Gy 68.12 2.67 67.85 2.46 68.69 3.15 69.84 1.23 <0.0001*
Mean no. fractions ± SD 32.17 2.59 31.9 2.34 32.77 3.10 33.43 2.13 <0.0001*
Chemotherapy
 Induction 98 16.7 76 78 22 22 - - 0.0001*
 Concurrent 220 37.5 155 71 63 29 2 <1
 Induction + Concurrent 129 21.8 75 58 45 36 8 6
 None 141 24.0 113 80 24 17 4 3
Surgery
 Yes 12 2.0 11 92 1 8 - - 0.29
 No 575 98.0 408 71 153 27 14 2
Mean survival time at survey (years) ± SD 5.94 2.86 5.75 2.87 6.41 2.79 6.14 2.71 0.0321*

Abbreviations: SD, Standard deviation; NOS, Not otherwise specified; GPS, Glossopharyngeal sulcus; Gy, Gray Group mean and categorical variables were compared with Kruskal-Wallis test and Pearson’s chi-square test, respectively.